In this study, we have shown that application of AKT or PI3K inhibitors during REP stage of TIL from cervical or ovarian cancer favors generation of the effector CD8+ T cell population with higher activation marker expression and more TCF‐1+ and CD39‐CD69‐ memory T cells in both CD4+ and CD8+ T cell populations, even while failing to impact, or even enhance TIL proliferation post‐REP. The gene discussed is PIK3CD; the disease is ovarian carcinoma.